



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/425,742	10/22/1999	KARL THEODOR KRAEMER	DEAV1998/L071 US NP	9957
22852	7590	12/14/2006	EXAMINER	
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP 901 NEW YORK AVENUE, NW WASHINGTON, DC 20001-4413			YU, GINA C	
			ART UNIT	PAPER NUMBER
			1617	

DATE MAILED: 12/14/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

09/425,742

Applicant(s)

KRAEMER ET AL.

Examiner

Gina C. Yu

Art Unit

1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 26 September 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-23, 28, 29 and 39-44 is/are pending in the application.
- 4a) Of the above claim(s) 3, 9 and 41-44 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1, 2, 4-8, 10-23, 28, 29, 39, 40 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some \* c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                       | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

### DETAILED ACTION

Receipt is acknowledged of response filed on September 26, 2006. Claims 1-23 and 28, 29, 39-44 are pending, of which claims 3, 9, 41-44 are withdrawn from consideration. All rejections made under 35 U.S.C. § 103 (a) as being unpatentable, as indicated in the previous Office action dated March 27, 2006, are withdrawn in view of further consideration in part, and in view of applicants' remarks in part. New rejections are made.

#### ***Claim Rejections - 35 USC § 103***

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

**Claims 1, 2, 4, 7, 8, 11-13, 16, 17, 22, 23, 28, and 29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Partain, III et al. (US 4946870) in view of Encyclopedia of Controlled Drug Delivery, (Vol. 1 & 2, 1999) and Gaillard-Kelly et al. (US 5411981).**

Partain teaches a topical film-forming composition for delivering pharmaceutical actives with controlled release. The reference teaches that the composition is useful as a delivery system for single or combination of pharmaceutical active agents, including antiacne agents (retinoic acid and benzoyl peroxide) and anti-alopecia agents (Minoxidil). See col. 9, lines 15 –16; Examples 1, 15, and 18. See instant claims 22, 23, 28, and 29. The reference also teaches using pharmaceutical actives including diazoxide and nifedipine, diltiazem are taught in col. 8, lines 55 – 58. See instant claims 11 and 12. The reference teaches that chitosan derivatives are useful film formers and topically applied in the form of lotion, solution, cream, etc. See col. 3, lines 28 – 52. The

polymer is said to readily form a film and "acts as a reservoir to continuously deliver the actives as well as protect the tissue from further injury or insult", which negates the need of hair cover. The reference goes on to teach that the film gives uniform distribution of the active on the tissue and prevents the migration or loss of the active from the site of application, and helps to control the dosage at a constant level. The reference also teaches using solvents including ethanol and glycerine with the chitosan film-forming agent. See col. 9, line 58 –66; col. 10, lines 10-17; Example 14.

Partain does not specifically mention that a plasticizer is used in the composition, but glycerine, as used in Example 14, is a well-known plasticizer in controlled release pharmaceutical art. See Encyclopedia of Controlled Drug Delivery, p. p. 307, Table 1; p. 309.

Partain fails to teach the compound of instant formula I.

Gaillard-Kelly et al. teach that the phenylimidazolidines of instant formula I have anti-androgenic activity and are used in pharmaceutical compositions including creams, pomades, and lotions. See col. 9, lines 29 – 36. The reference teaches that the compositions useful for treatment of acne and androgenic alopecia, among others. See col. 9, lines 43 – 55. The reference specifically teaches that the compositions are "useful in dermatology" and can be used antiacne components such as retinol or with a product stimulating the growth of hair such as Minoxidil (6-amino-4-(4-piperidino-1, 2-dihydro-1-hydroxy-2-iminopyridimidine) for the treatment of alopecia. See col. 9, lines 56 – 65. See instant claims 11, 13, and 23. Example 96 teaches 4-[3-(4-hydroxybutyl)-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)benzonitrile. See instant

Art Unit: 1617

claim 4. The reference also teaches adding to the composition 5 alpha-reductase inhibitor, which meets instant claims 16 and 17. See col. 9, lines 56 – 61. The reference also teaches that glycols are suitable excipients for the compound. See col. 9, lines 38-42.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the teaching of Partain III by adding to the controlled-release formulation the compound of instant formula I, as motivated by Gaillard-Kelly (a) both references teach anti-alopecia compositions in topical formulations such as creams and lotions; and (b) Gaillard-Kelly teaches that the phenylimidazolidines are combined with other hair growth agents such as Minoxidil, which is also used in Partain invention. The skilled artisan would have had a reasonable expectation of successfully producing a stable, and enhanced anti-alopecia formula with constant, timed-release of the active ingredients, which protects the applied area of the skin.

**Claim 14 is rejected under 35 U.S.C. 103(a) as being unpatentable over Partain, Gaillard-Kelly, and Encyclopedia of Controlled Drug Delivery as applied to claims 1, 2, 4, 7, 8, 11-13, 16, 17, 22, 23, 28, and 29 as above, and further in view of Lai (US 5916910).**

The combined references fail to teach angiotensin converting enzyme inhibitors.

Lai teaches conjugates of dithiocarbamates with pharmacologically active agents, wherein dithiocarbamates are said to reduce cutaneous irritation and alopecia. See col. 3, lines 49-51. Captopril, fosinopril, felodipine, nicardipine, and nifedipine are

taught as pharmaceutical agents that are added for modification. See col. 8, lines 51-54.

It would have been obvious to one of ordinary skill in the art at the time the present invention was made to have modified the teachings of the combined references by adding to the composition captopril as motivated by Lai because all the references are directed to treating alopecia, and Lai teaches that captopril are combined with other anti-alopecia agents. The skilled artisan would have had a reasonable expectation of successfully producing a composition that treats alopecia and hypertension.

**Claim 15 is rejected under 35 U.S.C. 103(a) as being unpatentable over Partain, Gaillard-Kelly, and Encyclopedia of Controlled Drug Delivery as applied to claims 1, 2, 4, 7, 8, 11-13, 16, 17, 22, 23, 28, and 29 as above, and further in view of Ismail (US 5541220).**

Partain, Gaillard, and Encyclopedia of Controlled Drug Delivery fail to teach methylxanthine compounds.

Ismail teach agents for the treatment protection of the skin. Exemplified is a capsule that can treat alopecia, which comprises pentoxifylin, vitamin E, and other ingredients.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to add pentoxifylin to the composition of the composition of the combined references because Ismail and the references are directed to treating alopecia and Ismail teach pentoxifyline as increasing blood circulation. The skilled artisan would have been motivated to add pentoxifyline to the composition of the

combined references because of the expectation of circulating the active agents of the composition through the body.

**Claims 18 and 19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Partain, Gaillard-Kelly, and Encyclopedia of Controlled Drug Delivery as applied to claims 1, 2, 4, 7, 8, 11-13, 16, 17, 22, 23, 28, and 29 as above, and further in view of Gaetani et al. (EP 0427625 A).**

Gaillard-Kelly teaches to combine phenylimidazolidines with a product stimulating the growth of hair for the treatment of alopecia. See col. 9, lines 55 – 65. The reference fails to teach 2,4-diamino-6-butoxy-3-sulfopyrimidine hydroxide.

Gaetani teaches internal salts of 2,4-diamino-6-alkoxy-3-sulfoxypyridimine hydroxide for combating hair loss and inducing/stimulating hair growth. See abstract. Specifically disclosed is 2,4-diamino-6-butoxy-3-sulfoxypyridimidine hydroxide. See Example de composition 2 and 3.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the composition of the combined references by adding 2,4-diamino-6-butoxy-3-sulfopyrimidine hydroxide to the composition, as motivated by Gaetani, because (a) the references are all directed toward combating hair loss; and (b) Gaillard-Kelly teaches to combine the phenylimidazolidines with hair growth stimulating agents to make an anti-alopecia composition. The skilled artisan would have been motivated to add 2,4-diamino-6-butoxy-3-sulfopyrimidine hydroxide to the composition of the combined references because of the expectation of further combating hair loss.

**Claims 18 and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Partain, Gaillard-Kelly, and Encyclopedia of Controlled Drug Delivery as applied to claims 1, 2, 4, 7, 8, 11-13, 16, 17, 22, 23, 28, and 29 as above, and further in view of applicants' own disclosure and Hocquaux et al. (WO 92/21317).**

Gaillard-Kelly teaches to combine the phenylimidazolidines with a product stimulating the growth of hair for the treatment of alopecia. See col. 9, lines 55 – 65. The combined references fail to teach 2, 6-diamino-4-piperidinopyridine.

Hocquaux ('317) teaches compositions containing a pyridine-1-oxide for combating hair loss and inducing/stimulating hair growth. See '701, abstract. 2,6-diamino 4-peperdinopyridine 1-oxide is disclosed in Example 1. See instant claims 18 and 20.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to add the 2,6-diamino 4-peperdinopyridine 1-oxide to the composition of the combined references because (a) the references are all directed toward combating hair loss; and (b) Gaillard-Kelly teaches to combine the phenylimidazolidines with other hair growth stimulating agents to make an anti-alopecia composition. The skilled artisan would have been motivated to add 2,4-diamino-6-butoxy-3-sulfonylpyrimidine hydroxide to the composition of the combined references because of the expectation of successfully producing an enhanced composition for combating hair loss.

**Claims 18 and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Partain, Gaillard-Kelly, and Encyclopedia of Controlled Drug Delivery as**



**applied to claims 1, 2, 4, 7, 8, 11-13, 16, 17, 22, 23, 28, and 29 as above, and further in view of Hocquaux et al. (WO 91/19701).**

Gaillard-Kelly teaches to combine phenylimidazolidines with a product stimulating the growth of hair for the treatment of alopecia. See col. 9, lines 55 – 65. The combined references fail to teach 2,6-diamino-4-butoxy-1,3,5-triazine 1-oxide.

Hocquaux ('701) teaches compositions containing 2, 6-diamino-1,3,5-triazine derivatives for combating hair loss and inducing/stimulating hair growth. See abstract. 2,6-diamino-4-butoxy-1,3,5-triazine 1-oxide is disclosed in Examples.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to add 2,6-diamino-4-butoxy-1,3,5-triazine 1-oxide to the composition of the combined references because Hocquaux ('701), because (a) the references are all directed toward combating hair loss; and (b) Gaillard-Kelly teaches to combine the phenylimidazolidines with hair growth stimulating agents to make an anti-alopecia composition. The skilled artisan would have been motivated to add the triazole compound of the Hocquaux ("701) to the composition of the combined references because of the expectation of successfully producing an enhanced composition for combating hair loss.

**Claims 5 and 6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Partain, Gaillard-Kelly, and Encyclopedia of Controlled Drug Delivery as applied to claims 1, 2, 4, 8, 11-13, 22, 23, 28, 29, 39, and 40 as above, and further in view of Cremophor RH 40 Technical Information (1997).**

The combined references fail to teach polyoxyethylene hydrogenated castor oil.

Cremophor RH 40 Technical Information (Cremophor) teaches that POE hydrogenated castor oil is skin compatible and solubilizes hydrophobic pharmaceuticals including vitamin A (retinoic acid). See Solubilization. The reference teaches that the product forms clear solutions in water and ethanol with fatty acids and fatty alcohols. See Solubility.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the composition of the combined references by adding to the composition POE hydrogenated castor oil as motivated by Cremophor because (a) Gaillard, Partain, and Cremophor all teach using retinoic acid; and (b) Cremophor teaches that POE hydrogenated castor oil is a well known solubilizer in pharmaceutical/cosmetic art, which solubilizes hydrophobic pharmaceutical agents to form a clear solution. The skilled artisan would have had a reasonable expectation of successfully producing a stable, clear cosmetic composition comprising retinoic acid and the compound of instant formula (I).

**Claims 1, 2, 4, 7, 10-13, 22, 23, 28, 29, 39, and 40 are rejected under 35 U.S.C. 103(a) as being unpatentable over Smith (US 5658559) in view of Gaillard-Kelly and Encyclopedia of Controlled Drug Delivery.**

Smith teaches a film-forming lotion composition which forms barrier on the surface of the skin to prevent evaporative loss of moisture from the skin, and protects the skin from environmental irritants. Polyvinylpyrrolidone/eicosene copolymers, polyvinylpyrrolidone/vinyl acetate copolymers, and polyvinylpyrrolidone/hexadecane copolymers are taught in col. 4, lines 14 – 32. See instant claim 10. The composition

Art Unit: 1617

also contains polysaccharide polymers which release the therapeutic agents in a time-controlled manner. See col. 4, lines 33 – 43. Also taught is polyquaternary polyvinylpyrrolidone such as polyquaternium-16 (polyvinylpyrrolidone/imidazolinium methochloride copolymers). See instant claims 39 and 40. The therapeutic agents include antiacne actives including benzoyl peroxide and vitamin A. See col. 5, lines 1-6. The composition of the invention comprises water and polyhydric alcohols such as propylene glycol and glycerine. See col. 8, lines 1 – 38. See instant claim 7.

Smith does not specifically mention that a plasticizer is used in the composition, but glycerine, as used in Example 14, is a well-known plasticizer in controlled release pharmaceutical art. See Encyclopedia of Controlled Drug Delivery, p. 307, Table 1; p. 309.

Smith fails to teach the compound of instant formula I.

Gaillard-Kelly, discussed above, teaches that the phenylimidazolidines of instant formula I is useful for treatment of acne, and further teaches to combine the active agent with retinol. See col. 9, lines 56 – 65. The formulations may be in the form of creams, pomades, and lotions. See col. 9, lines 29 – 36.

It would have been obvious to one of ordinary skill in the art at the time the present invention was made modify the teaching of Smith by adding to the occlusive, film-forming composition the phenylimidazolidine compound as motivated by Gaillard-Kelly, (a) both references are directed to acne treatment compositions with retinoid (Vitamin A); and (b) Smith teaches that the film-forming formulation provides controlled-release of the actives while protecting the skin and prevent loss of moisture of the skin;

and (c) Gaillard-Kelly teaches to combine the phenylimidazolidine compound with retinoid to make an anti-acne treatment composition. The skilled artisan would have had a reasonable expectation of successfully producing a stable and effective film-forming lotion which is useful for treating acne.

### ***Response to Arguments***

**Applicant's arguments filed on September 26, 2006 have been fully considered but they are not persuasive in part.**

Applicants' arguments regarding claims 18-21 are persuasive, and new rejections are made as above.

With respect to the primary rejection, applicants assert that the Office has not explained why a skilled artisan would have been motivated to selectively choose glycerin from among the long list of optional diluents and adjuvants, to be used with the compounds disclosed in Gaillard-Kelly. As indicated in the rejection, both Partain and Gaillard-Kelly are directed to analogous arts, i.e., the method of delivering anti-alopecia agents to the affected site in a controlled release delivery mechanism. The reference also teaches that glycerin-chitosan formulation produces a clear and color solution and shows an example. Applicants also assert "Partain already discloses compositions for the treatment of alopecia or acne that do not contain glycerin". As discussed above, the reference also teaches a glycerin-containing controlled-release formulation, which renders the use of glycerin an obvious choice.

Art Unit: 1617

It is also noted that, the claimed invention is directed to a composition, and the intended use of a particular component in the prior art composition cannot be the basis of patentable distinction.

Applicants assert that glycerin is an optional ingredient. Examiner respectfully disagrees, as the reference specifically exemplifies a glycerin-chitosan polymer composition. Examiner also disagrees with applicants' characterization of the discussion of a reference by the examiner. Applicants state, "the Office believes glycerin is a plasticizer". According to the cited reference that is well known and respected in applicants' art, glycerin is<sup>2</sup> a plasticizer. In response to applicants' assertion that the Office bears the burden as to what circumstances leads glycerin to act as a plasticizer, examiner respectfully disagrees. Examiner has produced evidence to show that 1) the use of a plasticizer in a controlled release formulation would have been obvious according to Encyclopedia of Controlled Drug Delivery; and 2) a skilled artisan in the particular art would have been aware that glycerin is a plasticizer, and 3) Partain formulation meets the instant claims as it teaches using glycerin. Examiner believes that a prima facie case of obviousness has been established because the rejection is fully supported by objective teachings and motivations found from the cited prior arts. Whether glycerin in a particular formulation would "impart suppleness and flexibility" to the chitosan film should be shown by applicants in order to rebut the rejection.

Regarding claim 14, applicants argue that Lai does not teach dithiocarbamate itself does not reduce irritation and alopecia. As acknowledged by applicants, the

Art Unit: 1617

reference teaches that administration of dithiocarbamate and an anti-cancer agent, as opposed to the anticancer agent alone, results in the reduced irritation and hair loss. Examiner views that, based on the teaching of the reference, a skilled artisan would have deduced that dithiocarbamate is responsible for the reduction of irritation and hair loss.

With respect to claim 15, applicants argue that Ismail fails to provide a specific motivation to add methylxanthine compounds to the composition of the combined references. In response, examiner respectfully points out that Ismail specifically provides an example which shows that it is well known in the art that pentoxifylin, a methylxanthine compound, is added in alopecia treatment composition to increase blood circulation of the patient.

With respect to claims 5 and 6, applicants assert that a routineer would have not been motivated to make modifications on the Partain compositions which already teaches suitable solvents. However, the rejection is made in view of the combined references, and the teachings of the cited references should be analyzed as a collective teaching. Given that Cremophor teaches that polyoxyethylene hydrogenated castor oil dissolves hydrophobic pharmaceuticals, such as retinoic acid, that are of interests of all other cited references, using this particular solubilizer to solubilize such pharmaceutical agents would have been an obvious choice.

With respect to the claim rejection made over Gaillard-Kelly in view of Smith and Controlled-Drug Delivery, applicants again argue that there is no evidence that glycerin is used as a plasticizer in the Smith formulation. In response, examiner reiterates that

Art Unit: 1617

the claimed invention is directed to a composition, and an allegedly different intended function of a particular component in the prior art composition cannot be the basis of patentable distinction. Furthermore, examiner already indicated with evidence that glycerin is known as a plasticizer in the particular art of applicants' endeavor. The burden of proving that glycerin does not meet the claimed limitation is on applicants.

### ***Conclusion***

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gina C. Yu whose telephone number is 571-272-8605. The examiner can normally be reached on Monday through Friday, from 8:00AM until 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1617

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



Gina C. Yu  
Patent Examiner